Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

ABSTRACT:

SUBMITTER: Dieras V 

PROVIDER: S-EPMC5531181 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature